A new class of chiral Lewis bases for the enantioselective HSiCl3-mediated reduction of imines was developed. Through extensive catalyst structure optimization, an extremely active species was identified that was able to promote the reduction of a large variety of functionalized substrates in high yields with enantioselectivities typically above 90% with catalyst loadings as low as 0.1-1 mol%. The simple experimental procedure, the low cost of the reagents, the mild reaction conditions, and the straightforward isolation of the product make the methodology attractive for large-scale applications. Its synthetic potentiality was demonstrated by the preparation of advanced intermediates of important active pharmaceutical ingredients used in the treatment of Alzheimer's and Parkinson's diseases, hyperparathyroidism, neuropathic pains, and neurological disorders. The reaction was also successfully performed in flow reactors, which thus demonstrated the possibility to realize in continuo processes to yield multigram quantities of product.
A new class of low-loading catalysts for a highly enantioselective, metal-free imine reduction of wide general applicability / D. Brenna, R. Porta, E. Massolo, L. Raimondi, M. Benaglia. - In: CHEMCATCHEM. - ISSN 1867-3880. - 9:6(2017 Mar), pp. 941-945. [10.1002/cctc.201700052]
A new class of low-loading catalysts for a highly enantioselective, metal-free imine reduction of wide general applicability
D. BrennaPrimo
;R. PortaSecondo
;E. Massolo;L. RaimondiPenultimo
;M. Benaglia
Ultimo
2017
Abstract
A new class of chiral Lewis bases for the enantioselective HSiCl3-mediated reduction of imines was developed. Through extensive catalyst structure optimization, an extremely active species was identified that was able to promote the reduction of a large variety of functionalized substrates in high yields with enantioselectivities typically above 90% with catalyst loadings as low as 0.1-1 mol%. The simple experimental procedure, the low cost of the reagents, the mild reaction conditions, and the straightforward isolation of the product make the methodology attractive for large-scale applications. Its synthetic potentiality was demonstrated by the preparation of advanced intermediates of important active pharmaceutical ingredients used in the treatment of Alzheimer's and Parkinson's diseases, hyperparathyroidism, neuropathic pains, and neurological disorders. The reaction was also successfully performed in flow reactors, which thus demonstrated the possibility to realize in continuo processes to yield multigram quantities of product.File | Dimensione | Formato | |
---|---|---|---|
Brenna_et_al-2017-ChemCatChem.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
701.76 kB
Formato
Adobe PDF
|
701.76 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
ChemCatChem_PostprintArtCatTriclosil.pdf
accesso aperto
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
224.5 kB
Formato
Adobe PDF
|
224.5 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.